A novel combination therapy of arginine deiminase and an arginase inhibitor targeting arginine metabolism in the tumor and immune microenvironment.
Pei-Hsuan Ye, Chung-Yen Li, Hao‐Yu Cheng, Gangga Anuraga, Chih‐Yang Wang, Feng‐Wei Chen, Shiang-Jie Yang, Kuo‐Ting Lee, Kwang‐Yu Chang, Ming‐Derg Lai
Abstract
TAMs, in tumors were dramatically decreased. Importantly, mechanistic analysis indicated that the processes of the cell cycle, ribonucleoprotein complex biogenesis, and ribosome biogenesis were upregulated after combination treatment. This study implied the possibility of L-Norvaline as a modulator of the immune response in cancer and provided a new potential therapy combined with ADI-PEG 20.
Topics & Concepts
ArginaseTumor microenvironmentCancer researchArginine deiminaseImmune systemNorvalineArginineArgininosuccinate synthaseChemistryCytotoxic T cellCD8Tumor progressionCancer cellBiologyCancerBiochemistryImmunologyIn vitroGeneGeneticsLeucineAmino acidCancer Research and TreatmentsCancer Immunotherapy and BiomarkersVirus-based gene therapy research